Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium

Tetrahedron Letters

Volumn 47, Issue 20, 2006, Pages 3387-3390

  Simmons, T Luke ^a,b   McPhail, Kerry L ^b   Ortega Barría, Eduardo ^c   Mooberry, Susan L ^d   Gerwick, William H ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Inst Invest Cie Avanzadas Y S   (Panama)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Dolastatins; Linear peptide; Marine natural products; Symploca sp.

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; BELAMIDE A; DOLASTATIN 10; DOLASTATIN 15; TETRAPEPTIDE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CYANOBACTERIUM; CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MARINE ENVIRONMENT; METHYLATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALIA; BACTERIA (MICROORGANISMS); SYMPLOCA;

EID: 33646023394     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2006.03.082     Document Type: Article

References (21)

1. Gerwick W.H., Tan L.T., and Sitachitta N. Nitrogen-containing metabolites from marine cyanobacteria. In: Cordell G. (Ed). The Alkaloids Vol. 57 (2001), Academic Press, San Diego 75-184
2. Pettit G.R., Kamano Y., Herald C.L., Tuinman A.A., Boettner F.E., Kizu H., Schmidt J.M., Baczynskyj L., Tomer K.B., and Bontems R.J. J. Am. Chem. Soc. 109 (1987) 6883-6885
3. Pettit G.R., Kamano Y., Dufresne C., Cerny R.L., Herald C.L., and Schmidt J.M. J. Org. Chem. 54 (1989) 6005-6006
4. Newman D.J., and Cragg G.M. J. Nat. Prod. 67 (2004) 1216-1238
5. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., and Gerwick W.H. Mol. Cancer Ther. 4 (2005) 333-342
6. Live algal sample collected on 11/3/03 at Salmedina Reef, Portobelo, Panama; N 09°33.799′ × W 79°41.642′; in shallow water by Drs. Kerry L. McPhail and William H. Gerwick.
7. Phenomenex Strata (Si-1; 55 μm particle) NP solid phase extraction column eluted with 100 mL of each the following solvent compositions, fraction: (A) [8:2] hexanes-EtOAc; (B) [1:1] hexanes-EtOAc; (C) 100% EtOAc; (D) 100% MeOH.
8. 2O.
9. -1.
10. 4 buffer.
11. Pettit, G. R. Inventor; Arizona Board of Regents, assignee. Synthesis of Dolastatin 10. United States Patent U.S. 4,978,744, 1990.
12. Bai R., Roach M.C., Jayaram S.K., Barkoczy J., Pettit G.R., Ludueña R.F., and Hamel E. Biochem. Pharmacol. 45 (1993) 1503-1515
13. Mitra A., and Sept D. Biochemistry 43 (2004) 13955-13962
14. Pettit G.R., Srirangam J.K., Barkoczy J., et al. Anti-Cancer Drug Design 13 (1998) 243-277
15. Miyakaki K., Kobayashi M., Natsume T., Gondo M., Mikami T., Sakakibara K., and Tsukagoshi S. Chem. Pharm. Bull. 43 (1995) 1706-1718
16. Luesch H., Moore R.E., Paul V.J., Mooberry S.L., and Corbett T.H. J. Nat. Prod. 64 (2001) 907-910
17. Bai R., Pettit G.R., and Hamel E. Biochem. Pharmacol. 40 (1990) 1859-1864
18. Poncet J., Busquet M., Roux F., Pierré A., Atassi G., and Jouin P. J. Med. Chem. 41 (1998) 1524-1530
19. Hamel E. Biopolymers (Pept. Sci.) 66 (2002) 142-160
20. Hamel E., and Covell D.G. Curr. Med. Chem.: Anti-Cancer Agents 2 (2002) 19-53
21. Spartan'04, Wavefunction, Inc., Irvine, CA.